IL-8 Receptor Modified Patient-Derived Activated CD70 CAR T Cell Therapy in Adults With Brain Metastases

Study acronym: IMPACT MET
StatusRecruiting
PhasePhase 1
Started

Free. We email you which fields changed when ClinicalTrials.gov updates this record.

Track this trial
View on ClinicalTrials.gov ↗

Record History

See every version on ClinicalTrials.gov ↗

  1. Recruitment opened Show 5 more changesShow less
    • Interventions modified
    • Start date: Oct 2026 to Oct 13, 2026
    • Eligibility criteria expanded, about 59 words
    • Study description expanded, about 33 words
    • Site details revised
  2. Start date: Jul 2026 to Oct 2026v2
  3. Study First Submitted
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
This is a Phase I Study evaluating the safety and feasibility of IL-8 receptor-modified patient-derived activated CD70 CAR T cells in adult patients with brain metastases from primary cancer, with either newly diagnosed lesions or recurrent or progressive disease after prior therapy.
Trial Details
NCT Number NCT07569263
Lead Sponsor University of Florida
Conditions
(from sponsor)		 Brain Metastases
Related terms Brain Neoplasms
Enrollment 12 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov